BST2 and ovarian carcinoma: 2016) (Figure 5C,D). Tetherin is overexpressed in a number of cancers, including multiple myeloma (Rew et al. 2005), ovarian cancer (Yang et al. 2022), and breast cancer (Cai et al. 2009; Sayeed et al. 2013), where its high expression is linked to poor prognosis (Sayeed et al. 2013; Mahauad‐Fernandez et al. 2018). Several studies have demonstrated that tetherin can promote cell adhesion (Mahauad‐Fernandez et al. 2018; Yoo et al. 2011), migration (Liu et al. 2018) and metastasis (Cai et al. 2009; Mahauad‐Fernandez et al. 2014, 2018).